fda ruling on compounding tirzepatide Did the Ban Compounded Semaglutide and Tirzepatide? Trimi GLP-1 Review 2026: What

Key findings from the evidence base include: Depression is not listed among the common adverse effects (occurring in 1/100 patients) in the UK Summary of Product Characteristics (SmPC) for Mounjaro Psychiatric adverse events were monitored but did not emerge as safety signals during phase 3 trials The most frequently reported side effects remain gastrointestinal (nausea, diarrhoea, vomiting, constipation) No mechanistic pathway has been established linking GIP/GLP-1 receptor agonism directly to depressive symptoms However, post-marketing surveillance continues to be crucial

Notice if you experience changes in thoughts, and track symptoms of depression and anxiety

If fatigue is accompanied by dizziness, weakness, or other unusual symptoms, it might require more urgent attention

Below it describes timing per guidelines, the physiologic rationale, who is most at risk, emergency exceptions, and pragmatic dosing principles

Bacteriostatic Water 10mL for reconstitution